Feed Top Reports Pricing

⌘K

07:28:58·2d

ANALYSTRating

Amphastar Pharmaceuticals downgraded by Jefferies with a new price target

AMPH· Amphastar Pharmaceuticals Inc.

Health Care

Original source

Companies

AMPH
Amphastar Pharmaceuticals Inc.
Health Care

Recent analyst ratings

Apr 21UpdateJefferies$22.00
Dec 9UpdateBarclays$30.00
Aug 12UpdateNeedham$36.00
May 12UpdateAnalyst$30.00
Feb 4UpdatePiper Sandler$36.00
Nov 22UpdateWells Fargo$55.00

Related

SEC10d
SEC Form DEFA14A filed by Amphastar Pharmaceuticals Inc.
SEC10d
SEC Form DEF 14A filed by Amphastar Pharmaceuticals Inc.
NEWS18d
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
SEC28d
Amendment: SEC Form SCHEDULE 13G/A filed by Amphastar Pharmaceuticals Inc.
INSIDER37d
EVP CORP ADMIN CENTER Liawatidewi Yakob covered exercise/tax liability with 1,033 shares, decreasing direct ownership by 0.84% to 121,892 units (SEC Form 4)
INSIDER37d
SENIOR EVP, PRODUCTION CENTER Zhou Rong covered exercise/tax liability with 1,225 shares, decreasing direct ownership by 0.71% to 171,554 units (SEC Form 4)
INSIDER37d
CFO, EVP & TREASURER Peters William J covered exercise/tax liability with 1,973 shares, decreasing direct ownership by 1% to 175,063 units (SEC Form 4)
INSIDER37d
CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. covered exercise/tax liability with 12,692 shares, decreasing direct ownership by 0.33% to 2,990,052 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022